Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

So VeriSign's still-low invested capital supports its high current ROIC. On an adjusted basis, the company's ROIC was 4.4% for 2023, with a five-year average of 3.9%, according to the data provided by ...

After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the presentation focused on the Cystic Fibrosis ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

In addition, Vertex is optimistic about the potential of its upcoming products like Alyftrek and suzetrigine. Alyftrek is positioned to capture a niche market of patients with specific mutations ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval molecule to a significant improvement from baseline, but placebo ...

JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which ...

Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...

This is the second time the series has received this accolade, following its initial win in 2023. Receiving this honor just one year after its first award highlights the Vertex S+ Black Series ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...